NCT04115241 Activity Levels in Bone Marrow Transplant Patients
| NCT ID | NCT04115241 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Michael Tomasson |
| Condition | Bone Marrow Transplant |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2019-05-23 |
| Primary Completion | 2030-05-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2019-05-23 with a primary completion date of 2030-05-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Participants in this study will be receiving a bone marrow transplant. This study is designed to evaluate correlations between activity levels and length of stay, quality of life, and hand grip strength.
Eligibility Criteria
Patients who will be receiving a bone marrow transplant are eligible for this study
Contact & Investigator
Michael Tomasson, MD
PRINCIPAL INVESTIGATOR
University of Iowa
Frequently Asked Questions
Who can join the NCT04115241 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Bone Marrow Transplant. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04115241 currently recruiting?
Yes, NCT04115241 is actively recruiting participants. Contact the research team at melissa-bates@uiowa.edu for enrollment information.
Where is the NCT04115241 trial being conducted?
This trial is being conducted at Iowa City, United States.
Who is sponsoring the NCT04115241 clinical trial?
NCT04115241 is sponsored by Michael Tomasson. The principal investigator is Michael Tomasson, MD at University of Iowa. The trial plans to enroll 200 participants.